DongKoo Bio&Pharma Co. Ltd (006620) — Cash Flow Quality Index
DongKoo Bio&Pharma Co. Ltd (006620) has a Cash Flow Quality Index of -0.96x as of June 2025. Operating cash flow of ₩-10.82 Billion is below net income of ₩11.29 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore 006620 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
DongKoo Bio&Pharma Co. Ltd Cash Flow Quality Index (2015–2024)
Historical Cash Flow Quality Index for DongKoo Bio&Pharma Co. Ltd across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check DongKoo Bio&Pharma Co. Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for DongKoo Bio&Pharma Co. Ltd (2015–2024)
Year-by-year earnings quality comparison for DongKoo Bio&Pharma Co. Ltd. For live market cap and the full company financial profile, see DongKoo Bio&Pharma Co. Ltd market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 8.71x | ₩17.34 Billion | ₩1.99 Billion | ▲ +2769.4% |
| 2023 | 0.30x | ₩3.59 Billion | ₩11.81 Billion | ▼ -88.1% |
| 2022 | 2.54x | ₩16.82 Billion | ₩6.61 Billion | ▲ +32.5% |
| 2021 | 1.92x | ₩17.90 Billion | ₩9.33 Billion | ▲ +134.3% |
| 2020 | 0.82x | ₩7.49 Billion | ₩9.14 Billion | ▲ +22.0% |
| 2019 | 0.67x | ₩10.14 Billion | ₩15.10 Billion | ▲ +487.8% |
| 2018 | -0.17x | ₩-791.20 Million | ₩4.57 Billion | ▼ -119.9% |
| 2017 | 0.87x | ₩9.51 Billion | ₩10.94 Billion | ▼ -24.7% |
| 2016 | 1.15x | ₩12.59 Billion | ₩10.91 Billion | ▼ -33.0% |
| 2015 | 1.72x | ₩6.93 Billion | ₩4.03 Billion | — |